2:18 PM
 | 
Sep 29, 2017
 |  BioCentury  |  Finance

Fueling up

How Autolus’ $80M series C round sets company up to advance CAR T pipeline

While crossovers joining Autolus Ltd.’s series C round don’t necessarily mean the chimeric antigen receptor T cell therapy company will follow fellow Syncona Ltd. (LSE:SYNC) portfolio company Nightstar Therapeutics plc (NASDAQ:NITE) to NASDAQ anytime soon, the financing does bring it a step closer to realizing investors’ ambitions of building a stand-alone commercial CAR T business.

On Tuesday, Autolus raised $80 million in a round led by founding investor Syncona, which invested $29.2 million to raise its stake to 38.4%. Existing investors Arix Bioscience plc...

Read the full 408 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >